Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results


1.		E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes and Refractory to the Most Recent Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				E7389-G000-301 NCT00337103


2.		E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				E7389-G000-305 NCT00388726

Last Modified: 1/23/2007 First Published: 8/13/2006


3.		Phase I/II Study of E7389 in Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Renal Insufficiency

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				CCC-PHII-75 7435, NCI-7435, NCT00365157

Last Modified: 9/9/2008 First Published: 5/23/2006


4.		Phase II Study of E7389 in Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				MSKCC-06027 7431, NCI-7431, NCT00334893

Last Modified: 10/8/2008 First Published: 6/9/2006


5.		Phase II Study of E7389 in Patients With Hormone-Refractory Metastatic Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				ECOG-E5805 E5805, NCT00337077

Last Modified: 4/12/2007 First Published: 2/16/2007


6.		Phase II Study of E7389 in Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other, Pharmaceutical / Industry				EORTC-62052 EISAI-E7389-E044-207, EUDRACT-2005-004272-20, NCT00413192


7.		Phase II Clinical Study of E7389 for Advanced or Relapsed Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				20 to 75				Pharmaceutical / Industry				E7389-J081-221 NCT00633100


8.		A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				E7389-A001-104 NCT00268905

Last Modified: 4/24/2008 First Published: 12/18/2006


9.		Phase I Study of E7389 and Cisplatin in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				CCC-PHI-55 7427, NCT00415324

Last Modified: 2/22/2007 First Published: 12/8/2006


10.		Phase I Study of E7389 and Gemcitabine Hydrochloride in Patients With Metastatic or Unresectable Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				PMH-PHL-048 7444, NCT00410553

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute